BIOX Strangle Strategy
BIOX (Bioceres Crop Solutions Corp.), in the Basic Materials sector, (Agricultural Inputs industry), listed on NASDAQ.
Bioceres Crop Solutions Corp., together with its subsidiaries, provides crop productivity solutions. It operates through three segments: Seed and Integrated Products, Crop Protection, and Crop Nutrition. The Seed and Integrated Products segment develops and commercializes seed technology, biotechnological events, germplasm, and seed treatments. The Crop Protection segment develops, produces, and markets Rizoderma, adjuvants, therapies, herbicides, insecticides, fungicides, and baits. The Crop Nutrition segment develops, produces, commercializes, and sells inoculants, bio-inductors, and biological and microgranulated fertilizers. The company also offers HB4, a drought tolerant seed technology program.
BIOX (Bioceres Crop Solutions Corp.) trades in the Basic Materials sector, specifically Agricultural Inputs, with a market capitalization of approximately $25.9M, a beta of 0.39 versus the broader market, a 52-week range of 0.347-5.175, average daily share volume of 745K, a public-listing history dating back to 2018, approximately 400 full-time employees. These structural characteristics shape how BIOX stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.39 indicates BIOX has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.
What is a strangle on BIOX?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
Current BIOX snapshot
As of May 15, 2026, spot at $0.44, ATM IV 22.40%, IV rank 1.05%, expected move 6.42%. The strangle on BIOX below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this strangle structure on BIOX specifically: BIOX IV at 22.40% is on the cheap side of its 1-year range, which favors premium-buying structures like a BIOX strangle, with a market-implied 1-standard-deviation move of approximately 6.42% (roughly $0.03 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated BIOX expiries trade a higher absolute premium for lower per-day decay. Position sizing on BIOX should anchor to the underlying notional of $0.44 per share and to the trader's directional view on BIOX stock.
BIOX strangle setup
The BIOX strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With BIOX near $0.44, the first option leg uses a $0.46 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed BIOX chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 BIOX shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $0.46 | N/A |
| Buy 1 | Put | $0.42 | N/A |
BIOX strangle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
BIOX strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on BIOX. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use strangle on BIOX
Strangles on BIOX are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the BIOX chain.
BIOX thesis for this strangle
The market-implied 1-standard-deviation range for BIOX extends from approximately $0.41 on the downside to $0.47 on the upside. A BIOX long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current BIOX IV rank near 1.05% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on BIOX at 22.40%. As a Basic Materials name, BIOX options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to BIOX-specific events.
BIOX strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. BIOX positions also carry Basic Materials sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move BIOX alongside the broader basket even when BIOX-specific fundamentals are unchanged. Always rebuild the position from current BIOX chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on BIOX?
- A strangle on BIOX is the strangle strategy applied to BIOX (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With BIOX stock trading near $0.44, the strikes shown on this page are snapped to the nearest listed BIOX chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are BIOX strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the BIOX strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 22.40%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a BIOX strangle?
- The breakeven for the BIOX strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current BIOX market-implied 1-standard-deviation expected move is approximately 6.42%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on BIOX?
- Strangles on BIOX are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the BIOX chain.
- How does current BIOX implied volatility affect this strangle?
- BIOX ATM IV is at 22.40% with IV rank near 1.05%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.